A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Basit Öğe Kaydı
dc.contributor.authorAkman Demir, Gulsen
dc.contributor.authorTurkoglu, Recai
dc.contributor.authorSaip, Sabahattin
dc.contributor.authorYuceyar, Nur
dc.contributor.authorEfendi, Husnu
dc.contributor.authorTuran, Omer Faruk
dc.contributor.authorKocer, Belgin
dc.date.accessioned2021-05-03T20:38:41Z
dc.date.available2021-05-03T20:38:41Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.descriptionBoz, Cavit/0000-0003-0956-3304; TERZI, Murat/0000-0002-3586-9115; YUCEYAR, NUR/0000-0003-4590-6423en_US
dc.description.abstractIntroduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents. Methods: Patients aged 18-65 years with RRMS who fulfilled the eligibility criteria were enrolled from 16 centers throughout Turkey. Treatment Satisfaction Questionnaire for Medication and 36-item Short-Form Health Survey were completed at baseline and four visits to assess patient satisfaction and quality of life. Results: Forty-two patients (62% male; mean age: 35.7 +/- 9.4 years) were eligible for inclusion. Patient satisfaction scores at the end of the study 44.7 +/- 9.9) were significantly higher than those at baseline [32.0 +/- 9.9; (p<0.001)]. The only significant increase in the quality of life survey was in the emotional aspect (p=0.019). There were 124 adverse events and none of the five serious adverse events noted was considered drugrelated. Conclusion: Large-scale comparative studies performed with disease specific quality of life instruments will allow more information on this issue.en_US
dc.description.sponsorshipNovartis, TurkeyNovartisen_US
dc.description.sponsorshipThis study is supported by a grant from Novartis, Turkey.en_US
dc.identifier.doi10.5152/npa.2017.20515en_US
dc.identifier.endpage257en_US
dc.identifier.issn1300-0667
dc.identifier.issn1309-4866
dc.identifier.issue4en_US
dc.identifier.pmid31903032en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage253en_US
dc.identifier.urihttps://doi.org/10.5152/npa.2017.20515
dc.identifier.urihttps://hdl.handle.net/11454/70522
dc.identifier.volume56en_US
dc.identifier.wosWOS:000510207600005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofNoropsikiyatri Arsivi-Archives of Neuropsychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple sclerosisen_US
dc.subjectfingolimoden_US
dc.subjectpatient satisfactionen_US
dc.subjectquality of lifeen_US
dc.titleA 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu